|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2875 SEK | +3.42% |
|
-5.89% | -97.12% |
| May. 22 | Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®? | CI |
| May. 16 | Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024 |
Redeye returns with a research update following Xbrane’s Q1 report. Sales and EBIT were lower than we had estimated, but end-customer sales grew 30%. The report prompts minor adjustments to our forecasts and valuation.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
© Modular Finance, source
| 1st Jan change | Capi. | |
|---|---|---|
| -97.12% | 40.69M | |
| +34.01% | 51.07B | |
| +33.84% | 38.86B | |
| -8.02% | 38.78B | |
| -8.98% | 26.69B | |
| +12.56% | 26.35B | |
| -19.62% | 19.46B | |
| +39.18% | 13.58B | |
| +31.47% | 12.46B | |
| -3.40% | 11.75B |
XBRANE BIOPHARMA AB 
